Durathate Dosage

sponsored
How long did you take this medication to work?

Dosage of Durathate in details

infoThe dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored

Durathate (Durathate (transdermal)) TTS

One system is applied at about the same time each day. The adhesive side of the Durathate (Durathate (transdermal)) TTS system should be placed on a clean, dry area of skin on the arm, back or upper buttocks immediately upon removal from the protective pouch. DO NOT APPLY TO THE SCROTUM. The area selected should not be oily, damaged, or irritated. The system should be pressed firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact, especially around the edges. In the event that a system should fall off, the same system may be reapplied. If the system comes off after it has been worn for more than 12 hours and it cannot be reapplied, a new system may be applied at the next routine application time. In either case, the daily treatment schedule should be continued. The Durathate (Durathate (transdermal)) TTS system should be worn approximately 24 hours and then replaced. To ensure proper dosing, serum Durathate concentration may be measured 2-4 hours after an application of Durathate (Durathate (transdermal)) TTS. If the serum Durathate concentrations are low, the dosing regimen may be increased to 2 systems. Because of variability in analytical values among diagnostic laboratories, all Durathate measurements should be performed at the same laboratory.

Durathate (Durathate (transdermal)) and Durathate (Durathate (transdermal)) WITH ADHESIVE

Patients should start therapy with a 6 mg/d system of either Durathate (Durathate (transdermal)) or Durathate (Durathate (transdermal)) WITH ADHESIVE applied daily; if the scrotal area cannot accommodate a 6 mg/d system, a 4 mg/d Durathate (Durathate (transdermal)) system should be used. One Durathate (Durathate (transdermal)) or Durathate (Durathate (transdermal)) WITH ADHESIVE system should be placed on clean, dry, scrotal skin. Scrotal hair should be dry-shaved for optimal skin contact. Chemical depilatories should not be used. Durathate (Durathate (transdermal)) or Durathate (Durathate (transdermal)) WITH ADHESIVE should be worn 22-24 hours.

After 3-4 weeks of daily system use, blood should be drawn 2-4 hours after system application for determination of serum total Durathate. Because of variability in analytical values among diagnostic laboratories, this laboratory work and later analyses for assessing the effect of the Durathate (Durathate (transdermal)) and Durathate (Durathate (transdermal)) WITH ADHESIVE therapy should be performed at the same laboratory.

If patients have not achieved desired results by the end of 6-8 weeks of treatment with any of the Durathate (Durathate (transdermal)) products, another form of Durathate replacement therapy should be considered.

How supplied

Durathate (Durathate (transdermal)) TTS, Durathate (Durathate (transdermal)), and Durathate (Durathate (transdermal)) WITH ADHESIVE Durathate transdermal systems contain a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.

Durathate (Durathate (transdermal)) TTS

Durathate (Durathate (transdermal)) TTS systems are supplied as individually pouched systems, 30 per carton. Durathate (Durathate (transdermal)) TTS 5 mg/d (Durathate Transdermal System) -- each 60 cm2 system contains 328 mg Durathate USP for nominal dose of 5 mg/day

Carton of 30 Durathate (Durathate (transdermal)) TTS 5 mg/d systemsNDC 17314-4717-3

Durathate (Durathate (transdermal)) and Durathate (Durathate (transdermal)) WITH ADHESIVE

Durathate (Durathate (transdermal)) and Durathate (Durathate (transdermal)) WITH ADHESIVE systems are supplied as individually pouched systems, 30 per carton.

Durathate (Durathate (transdermal)) 4 mg/d (Durathate Transdermal System) -- each 40 cm2 system contains 10 mg Durathate USP for nominal delivery of 4 mg for one day.

Carton of 30 Durathate (Durathate (transdermal)) 4 mg/d systems. NDC 17314-4608-3

Durathate (Durathate (transdermal)) and Durathate (Durathate (transdermal)) WITH ADHESIVE

6 mg/d (Durathate Transdermal System) -- each 60 cm2 system contains 15 mg Durathate USP for nominal delivery of 6 mg for one day.

Carton of 30 Durathate (Durathate (transdermal)) 6 mg/d systems. NDC 17314-4609-3

Carton of 30 Durathate (Durathate (transdermal)) WITH ADHESIVE 6 mg/d systemsNDC 17314-2836-3

Storage

Durathate (Durathate (transdermal)) TTS

Store at controlled room temperature below 25oC (77oF).

Durathate (Durathate (transdermal)) and Durathate (Durathate (transdermal)) WITH ADHESIVE

Store at room temperature 15-30oC (59-86oF).

Disposal

Durathate (Durathate (transdermal)) products should be discarded in household trash in a manner that prevents accidental application or ingestion by children or pets.

Caution: Federal law prohibits dispensing without prescription.

REFERENCE

1. Matsumoto AM, Sandblom RE, Schoene RB et al. Durathate replacement in hypogonadal men: Effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (1985) 22: 713-721.

2. Schneider BK, Pickett CK, Zwillich CW et al. Influence of Durathate on breathing during sleep. J Appl Physiol (1986) 61: 618-623.

3. Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am. (1994) 23: 857-875.

4. Bardin CW, Swerdloff RS, Santen RJ. Androgens: Risks and benefits. J Clin Endocinol Metab (1991) 73: 4-7.

5. Nieschlag E, Wang CCL. Guidelines for the use of androgens in men. Geneva: World Health Organization (1992); 1-16.

6. Walle T, Walle UK, Mathur RS et al. Propranolol metabolism in normal subjects: Association with sex steroid hormones. Curr Pharmacol Ther (1994) 56:127-132.

7. Physicians Generic Rx: The Complete Drug Reference. (1996); II-1972

What other drugs will affect Durathate?

Before using Durathate buccal system, tell your doctor if you are taking any of the following medicines:

  • warfarin (Coumadin);

  • insulin or an oral diabetes medication such as glipizide (Glucotrol), glyburide (Diabeta, Micronase, Glynase), repaglinide (Prandin), rosiglitazone (Avandia), pioglitazone (Actos), and others;

  • propranolol (Inderal, Inderal LA, others); or

  • a corticosteroid such as hydrocortisone (Cortef, Hydrocortone, Solu-Cortef), dexamethasone (Decadron, Hexadrol others), methylprednisolone (Depo-Medrol, Medrol, Solu-Medrol), prednisolone (Prelone, Pediapred), prednisone (Deltasone, Orasone, others), and others.

You may not be able to use Durathate buccal system, or you may require a dosage adjustment or special monitoring during treatment if you are taking any of the medicines listed above.

Drugs other than those listed here may also interact with Durathate buccal system. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including vitamins, minerals, and herbal products.

Durathate interactions

infoInteractions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Durathate, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored

Drug Interactions

Anticoagulants: C-17 substituted derivatives of Durathate, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped.

Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.

Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.

Propranolol: In a published pharmacokinetic study of an injectable Durathate product, administration of Durathate cypionate led to an increased clearance of propranolol in the majority of men tested.6

Corticosteroids: The concurrent administration of Durathate with ACTH or corticosteroids may enhance edema formation; thus these drugs should be administered cautiously, particularly in patients with cardiac or hepatic disease.7

Drug/Laboratory Test Interactions

Androgens may decrease levels of thyroxin-binding globulin, resulting in decreased total T. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

The Durathate (Durathate (transdermal)) products contain a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.

Durathate (Durathate (transdermal)) TTS is designed for application to arm, back or upper buttocks skin.

Durathate (Durathate (transdermal)) and Durathate (Durathate (transdermal)) WITH ADHESIVE are designed for application to scrotal skin only. Because scrotal skin is at least five times more permeable to Durathate than other skin sites, Durathate (Durathate (transdermal)) or Durathate (Durathate (transdermal)) WITH ADHESIVE will not produce adequate serum Durathate concentrations if applied to non-scrotal skin.

Ingestion of Durathate, or the contents of any of the Durathate (Durathate (transdermal)) products will not result in clinically significant serum Durathate concentrations due to extensive first-pass metabolism. In addition, an intramuscular injection of Durathate from any of the Durathate (Durathate (transdermal)) products will not produce adequate serum Durathate levels due to its short half-life (about 10 minutes).


sponsored

References

  1. DailyMed. "TESTOSTERONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. FDA/SPL Indexing Data. "3XMK78S47O: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
  3. MeSH. "Androgens". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Durathate are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Durathate. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


Consumer reported doses

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 20 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2020 ndrugs.com All Rights Reserved